Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

Author(s):

Y.S. Jung ◽

M. Kim ◽

J. H. Lee ◽

D.W. Kim ◽

H.J. Park

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Second Generation ◽

Kinase Inhibitors

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

British Journal of Haematology ◽

10.1111/j.1365-2141.2010.08245.x ◽

2010 ◽

Vol 150 (3) ◽

pp. 303-312 ◽

Cited By ~ 24

Author(s):

Fabio P. S. Santos ◽

Hagop Kantarjian ◽

Carmen Fava ◽

Susan O’Brien ◽

Guillermo Garcia-Manero ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Second Generation ◽

Kinase Inhibitors ◽

Clinical Impact ◽

Dose Reductions

A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia

Leukemia Research ◽

10.1016/j.leukres.2013.04.003 ◽

2013 ◽

Vol 37 (7) ◽

pp. 752-758 ◽

Cited By ~ 8

Author(s):

Sebastian Francis ◽

Claire Lucas ◽

Steven Lane ◽

Lihui Wang ◽

Sarah Watmough ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Population Study ◽

Second Generation ◽

Kinase Inhibitors ◽

Progression Free Survival ◽

Free Survival

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors

British Journal of Haematology ◽

10.1111/bjh.14783 ◽

2017 ◽

Vol 182 (3) ◽

pp. 427-429 ◽

Author(s):

Matteo Molica ◽

Martina Canichella ◽

Gioia Colafigli ◽

Roberto Latagliata ◽

Daniela Diverio ◽

...

Keyword(s):

Body Mass Index ◽

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Body Mass ◽

Second Generation ◽

Kinase Inhibitors ◽

Response Rate ◽

Molecular Response

A Comparison of Methodologies for Estimating Survival in Patients Treated with Second-generation Tyrosine-kinase Inhibitors (TKIs) for Chronic Myeloid Leukaemia (CML)

Value in Health ◽

10.1016/j.jval.2013.08.023 ◽

2013 ◽

Vol 16 (7) ◽

pp. A326-A327 ◽

Author(s):

B. Pennington ◽

A.J. Batty ◽

E. Clifton-Brown

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Second Generation ◽

Kinase Inhibitors

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study

The Lancet Haematology ◽

10.1016/s2352-3026(19)30087-0 ◽

2019 ◽

Vol 6 (8) ◽

pp. e398-e408 ◽

Cited By ~ 17

Author(s):

Ya-Chen Tina Shih ◽

Jorge E Cortes ◽

Hagop M Kantarjian

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Second Generation ◽

Kinase Inhibitors ◽

Treatment Free Remission ◽

Modelling Study

Erratum to: Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)

BioDrugs ◽

10.1007/s40259-014-0093-2 ◽

2014 ◽

Vol 28 (3) ◽

pp. 325-325 ◽

Author(s):

Elisabetta Abruzzese ◽

Massimo Breccia ◽

Roberto Latagliata

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Second Generation ◽

Kinase Inhibitors ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)

BioDrugs ◽

10.1007/s40259-013-0056-z ◽

2013 ◽

Vol 28 (1) ◽

pp. 17-26 ◽

Cited By ~ 14

Author(s):

Elisabetta Abruzzese ◽

Massimo Breccia ◽

Roberto Latagliata

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Second Generation ◽

Kinase Inhibitors ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors

Współczesna Onkologia ◽

10.5114/wo.2016.64607 ◽

2016 ◽

Vol 5 ◽

pp. 414-417

Author(s):

Agnieszka Piekarska ◽

Lidia Gil ◽

Karolina Jakitowicz ◽

Witold Prejzner ◽

Mieczysław Komarnicki ◽

...

Keyword(s):

Quality Of Life ◽

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Cell Transplantation ◽

Second Generation ◽

Kinase Inhibitors ◽

Haematopoietic Cell

Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study

British Journal of Haematology ◽

10.1111/j.1365-2141.2011.08653.x ◽

2011 ◽

Vol 155 (1) ◽

pp. 128-130 ◽

Cited By ~ 7

Author(s):

Paolo Gallipoli ◽

Pat Shepherd ◽

David Irvine ◽

Mark Drummond ◽

Tessa Holyoake

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Population Study ◽

Second Generation ◽

Kinase Inhibitors ◽

Restricted Access ◽

The Uk

Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients

Leukemia ◽

10.1038/leu.2015.71 ◽

2015 ◽

Vol 29 (7) ◽

pp. 1514-1523 ◽

Cited By ~ 18

Author(s):

C M Lucas ◽

R J Harris ◽

A K Holcroft ◽

L J Scott ◽

N Carmell ◽

...

Keyword(s):

High Risk ◽

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Disease Progression ◽

Second Generation ◽

Kinase Inhibitors